SPONSOR
Gruppo Oncologico del Nord-Ovest
Total Trials
4
Recruiting
4
Phases
Phase 2, Phase 3
Conditions studied: Head and Neck Squamous Cell Carcinoma (HNSCC)Recurrent Head and Neck CancerMetastatic Head and Neck CancerColorectal CancerGastric CancerHER2-positive Gastric CancerResectable Colorectal Carcinoma
Gruppo Oncologico del Nord-Ovest is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, Colorectal Cancer.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Gruppo Oncologico del Nord-Ovest
How many clinical trials has Gruppo Oncologico del Nord-Ovest sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Gruppo Oncologico del Nord-Ovest, of which 4 are actively recruiting participants. These trials cover conditions including Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Gruppo Oncologico del Nord-Ovest research focus on?
Gruppo Oncologico del Nord-Ovest clinical trials span Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, Colorectal Cancer, Gastric Cancer, and additional conditions. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Gruppo Oncologico del Nord-Ovest clinical trial?
To participate in a Gruppo Oncologico del Nord-Ovest trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Gruppo Oncologico del Nord-Ovest trials with current recruitment status updated daily.
Clinical Trials by Gruppo Oncologico del Nord-Ovest
NCT06869473 Phase 2
Recruiting
Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.
Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT06733038 Phase 3
Recruiting
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
Colorectal Cancer
NCT06253650 Phase 2
Recruiting
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Gastric Cancer
NCT05845450 Phase 2
Recruiting
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Colorectal Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology